[Amantadine]

Area of Science:

• Virology
• Pharmacology

Background:

• Amantadine, developed in 1964, was the first human antiviral medication.
• It exhibits selective, dose-dependent efficacy against the Type A influenza virus.

Observation:

• The drug is most effective when administered within 48 hours of influenza symptom onset.
• Recommended daily dosages vary by age and renal function: not exceeding 150 mg for children, 200 mg for adults, and under 100 mg for those with renal insufficiency.

Findings:

• Influenza A viruses can develop resistance to amantadine through mutations in the M2 protein's ion channel.
• However, amantadine-resistant strains are generally less virulent and have a limited lifespan.
• The development of rapid diagnostic kits for influenza enhances the utility of amantadine.

Implications:

• Amantadine remains a cost-effective option for treating Type A influenza, particularly when rapid diagnostics confirm infection.
• It serves as a viable alternative, especially during shortages of neuraminidase inhibitor drugs.
• Understanding resistance mechanisms is crucial for optimizing antiviral therapy strategies.